Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224

2018 Gastrointestinal Cancers Symposium
Tweet this page

Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Abstract 209).

Advertisement

Advertisement



Advertisement